Synthesis and In Silico Study of Some New bis-[1,3,4]thiadiazolimines and bis-Thiazolimines as Potential Inhibitors for SARS-CoV-2 Main Protease

Sobhi M. Gomha 1,* Sayed M. Riyadh 2,3, Magda H. Abdellattif 4, Tariq Z. Abolibda 1, Hassan M. Abdel-aziz 5, AbdElAziz. A. Nayl 6, Alaa M. Elgohary 7 and Abdo A. Elfiky 7,*

1 Department of Chemistry, Faculty of Science, Islamic University of Madinah, Madinah 42351, Saudi Arabia
2 Department of Chemistry, Faculty of Science, Cairo University, Giza 12613, Egypt
3 Department of Chemistry, Faculty of Science, Taibah University, Al-Madinah Al-Munawarah 30002, Saudi Arabia
4 Department of Chemistry, College of Science, Taif University, P.O. Box 11099, Taif 21944, Saudi Arabia
5 Department of Chemistry, Faculty of Science, Bani Suef University, Bani Suef 62521, Egypt
6 Department of Chemistry, College of Science, Jouf University, Sakaka 72341, Saudi Arabia
7 Department of Biophysics, Faculty of Science, Cairo University, Giza 12613, Egypt
* Correspondence: smgomha@iu.edu.sa (S.M.G.); dr_abdo@cu.edu.eg (A.A.E.)

Abstract: A novel series of bis-[1,3,4]thiadiazolimines, and bis-thiazolimines, with alkyl linker, were synthesized through general routes from cyclization of 1,1′-(hexane-1,6-diyl)bis(3-phenylthiourea) and hydrazonoyl halides or α-haloketones, respectively. Docking studies were applied to test the binding affinity of the synthesized products against the Mpro of SARS-CoV-2. The best compound, 5h, has average binding energy (−7.50 ± 0.58 kcal/mol) better than that of the positive controls O6K and N3 (−7.36 ± 0.34 and −6.36 ± 0.31 kcal/mol). Additionally, the docking poses (H-bonds and hydrophobic contacts) of the tested compounds against the Mpro using the PLIP web server were analyzed.

Keywords: bis-(3-phenylthiourea); hydrazonoyl halides; α-haloketones; molecular docking; SARS-CoV-2 Mpro

1. Introduction

Recently, COVID-19 vaccines have been developed and evaluated to be validated for use [1–4]. Thus, many researchers orchestrated their efforts to formulate and construct novel bioactive bis-heterocycles as antiviral agents and other therapeutic effects. It has been reported in the literature that compounds containing bis-thiadiazole cores have attracted considerable interest in the area of drug discovery due to their potential as anti-hypertensive α-blocking [5], antimicrobial [6–8], and anticancer [9,10] agents. In addition, bis-thiazole pharmacophores were reported to reveal various biological activities such as anti-inflammatory, analgesic, anti-ulcerogenic [11], antiviral [12], antimicrobial [13,14], antioxidant [15], and anticancer activities [16–19]. Moreover, azoles tethered imines are accentuated to investigate new potential drug candidates with diverse therapeutic efficacy such as antibacterial, antifungal, anticancer, antioxidant, and antiproliferative activities [20–25]. So, molecular hybridization of imines and azoles is a beneficial approach to structural alteration, as a single species of two or more pharmacophores can serve as potential COVID-19 drug candidates [26].

bis-1,3-Thiazole derivatives were examined against different viruses (such as hepatitis B and C viruses, poliovirus, and influenza A virus) and showed promising results (up to EC50 0.56 μM) [12].

The main protease (Mpro) or 3CLpro is a vital viral protein that is important for the SARS-CoV-2 life cycle. Its function is to process viral polyprotein upon entry and replication
in the host cell [27]. Due to its conservation among different coronaviruses, it is one of the most studied targets in SARS-CoV-2 research, while the dimer form represents the active conformation of the functional enzyme [28–31]. Some drugs are potential candidates that block \( M^\text{pro} \) function, such as Paxlovid, which consists of two drugs, nirmatrelvir (protease inhibitor) and ritonavir (nirmatrelvir bioavailability enhancer). Paxlovid was approved for COVID-19 patients in Europe, while other drugs are in clinical trials [32–34].

In this study, the combination of \emph{bis}-thiazoles or \emph{bis}-thiazoles with imine moiety in a hybridized molecule was achieved, and the synthesized derivatives were docked against the main protease \((M^\text{pro})\) of SARS-CoV-2. The docked complexes are analyzed using molecular modeling tools, including molecular docking and dynamics simulation.

2. Results and Discussion

1,1′-(Hexane-1,6-diyl)bis(3-phenylthiourea) (1), derived from hexamethylenediamine and phenyl isothiocyanate [35,36], was allowed to react with hydrazonoyl chlorides \( 2 \) in ethanolic solution containing a few drops of triethylamine resulting in the formation of \( N,N^\prime\)-(hexane-1,6-diyl)bis[5-substituted-3-aryl-1,3,4-thiadiazol-2(3H)-imine] \( 5\text{a–h} \) as target compounds. The synthetic pathway is depicted in Scheme 1.

| Compd | R      | Ar       | Compd | R      | Ar       |
|-------|--------|----------|-------|--------|----------|
| 2a, 5a| COCH\(_3\) | Ph       | 2e, 5e| COOC\(_2\)\(_4\)H\(_5\) | 2-CH\(_2\)\(_2\)C\(_6\)H\(_4\) |
| 2b, 5b| COCH\(_3\) | 4-CH\(_2\)\(_2\)C\(_6\)H\(_4\) | 2f, 5f| COOC\(_2\)\(_4\)H\(_5\) | 4-ClC\(_6\)H\(_4\) |
| 2c, 5c| COCH\(_3\) | 4-ClC\(_6\)H\(_4\) | 2g, 5g| COOC\(_2\)\(_4\)H\(_5\) | 2,4-(Cl\(_2\))C\(_6\)H\(_3\) |
| 2d, 5d| COCH\(_3\) | 2,4-(Cl\(_2\))C\(_6\)H\(_3\) | 2h, 5h| PhNHCO | Ph |

\( \text{Scheme 1. Synthesis of } \text{bis-[1,3,4]thiadiazolimines } 5\text{a–h.} \)
The synthesis of bis-[1,3,4]thiadiazol-2-imines 5a–h was inaugurated by nucleophilic halogen displacement by the thiol group to afford intermediate 3. Intramolecular cyclization of the latter intermediate with consecutive elimination of aniline molecules furnished the isolated products in good yields (Scheme 1). The spectroscopic data (IR, 1H-NMR, 13C-NMR, and MS) and the elemental analyses of bis-[1,3,4]thiadiazol-2-imines 5a–h were in agreement with the assigned structures (see Experimental section).

The scope of the previous hetero-cyclization was expanded with respect to α-haloketones. Thus, we explored the cyclo-condensation reaction of 1,1’-(hexane-1,6-diyl)bis(3-phenylthiourea) (1) with substituted phenacyl bromides 6a–e or 3-chloro-2,4-pentanedione (9a) or ethyl 2-chloro-3-oxobutanoate (9b) under the employed conditions and the desired bis-thiazol-2-imines 8a–e, or 11a, or 11b, respectively, were obtained in acceptable yields through the proposed mechanistic pathway illustrated in Scheme 2. This indicated that the synthetic utility of bis(3-phenylthiourea) with an alkyl linker could improve bis-heterocyclic scaffolds, enhancing their biological activities.

![Scheme 2. Synthesis of bis-thiazolimines 8a–e and 11a,b.](image)

3. Computational Analysis

Molecular docking combined with molecular dynamics simulation was utilized to test the binding affinity of starting material 1, bis-[1,3,4]thiadiazol-2-imines 5a–h, and bis-thiazol-2-imines (8a–e and 11a,b) against the M\textsuperscript{pro} of SARS-CoV-2. The solved structure used in this study is the dimeric M\textsuperscript{pro} (PDB ID: 6Y2G), this is due to the fact that it is the active dimeric form of the M\textsuperscript{pro} and solved with O6K inhibitor (tert-butyl (1-((S)-1-(((S)-4-(benzylamino)-
3,4-dioxo-1-((S)-2-oxopyrrolidin-3-yl)]butan-2-yl)amino)-3-cyclopropyl-1-oxopropan-2-yl)2-oxo-1,2-dihydrorypidin-3-yl)carbamate (alpha-ketoamide 13b)), so we extracted it and used it as positive control. Additionally, we used the other inhibitor N3 (N-[(5-methylisoxazol-3-yl)carbonyl]alanyl-L-valyl-N-1-((1R,2Z)-4-(benzyloxy)-4-oxo-1-[(3R)-2-oxopyrrolidin-3-yl)methyl][but-2-ethyl]-L-leucinamide) found in the solved structure 6LU7 to compare its affinity to M\textsuperscript{pro} to that of bis-[1,3,4]thiadiazolimines and bis-thiazolimines against the active site of the M\textsuperscript{pro}.

The docking was performed after equilibrating the structure for an 80 ns MDS run. The reason for performing MDS before docking is that we remove ligands and want the protein to be relaxed before making the docking calculations. We also equilibrate the system and cluster the trajectories to test different possible protein conformations against the compounds. Figure 1A reflects the system equilibration as the root-mean-square deviation (RMSD) curve (blue) is flattened around 2 Å. Additionally, the radius of the gyration (RoG) curve (red) is flat during the simulation period, averaging about 26 Å. Figure 1B shows the five representative models for M\textsuperscript{pro} after clustering the trajectories depicted in colored cartoons. Additionally, the per-residue root-mean-square fluctuations (RMSF) in Å are plotted. The active site residues (H41 and C145) are marked on the RMSF curve. In addition to the protein termini, only one region (S46-M49) shows moderate fluctuations (RMSF < 1.5 Å). This region is colored in red in the structures. The active site residues are away from this region and show low fluctuations (RMSF > 0.7 Å).

The bar graph of Figure 2A shows the average (out of five values) binding energy (in kcal/mol) against the M\textsuperscript{pro} of different SARS-CoV-2 conformations after MDS trajectory clustering. The error bars represent the standard deviation which was calculated by the Microsoft Excel formula \(\sqrt{\frac{\sum(x - \bar{x})^2}{n-1}}\). Before the docking of the compounds, we tested the docking system by performing a redocking of O6K to the solved structure and we obtained a root-mean-square deviation of 0.92 Å (1806 fitted atoms). The positive controls O6K and N3 (putative inhibitors to M\textsuperscript{pro} found in the solved structures 6Y2G and 6LU7) are shown in red and orange, respectively, while the compounds 1, 5a-h, 8a-e, and 11a,b are in blue (Figure 2A). The best compound, 5h, is shown in green. The compound 5h has average binding energy (−7.50 ± 0.58 kcal/mol) better than that of the positive controls O6K and N3 (−7.36 ± 0.34 and −6.36 ± 0.31 kcal/mol). Despite the fact that the binding affinity value of 5h compound is not significantly different compared to the positive control, it is still a potential anti-SARS-CoV-2 M\textsuperscript{pro} compound that deserves further investigation.

Figure 2B shows the detailed interaction pattern between 5h and the M\textsuperscript{pro}. Five hydrophobic contacts are formed between 5h and the residues F140, E166(2), P168, and Q189 of M\textsuperscript{pro}. Additionally, the other tested compounds (except compound 1) present enhanced binding energies against M\textsuperscript{pro} (−6.38 ± 0.52 down to −7.18 ± 0.29 kcal/mol for 11b and 8e, respectively) compared to the positive control N3. This reflects their potential to be tightly bound to and might inhibit the M\textsuperscript{pro} of SARS-CoV-2.

Furthermore, we analyzed the docking poses of the compounds against the M\textsuperscript{pro} using the PLIP web server, and a detailed list is tabulated (Table 1). The ligand that has the nearest binding affinity to the average value is represented. These modes resemble five different protein conformations after an 80 ns MDS run. For the compounds 5a, 5b, 5c, 5d, 5e, 5f, 5g, 11a, and 11b, the most common interactions are the H-bonds (three) and the hydrophobic contacts (three). On the other hand, only hydrophobic contacts (four) are reported in compounds 5h, 8a, 8b, 8c, 8d, and 8e, while compound 1 formed only two H-bonds with the M\textsuperscript{pro}. Compounds 5c, 5d, and 5g form a halogen bond with R188 or T190 residues of the M\textsuperscript{pro}. The highest contributing residues in the formed interactions between the compounds and the M\textsuperscript{pro} are Q189, E166, N142, G143, S144, and C145, which formed 14, 11, 8, 8, 8, and 5 interactions, respectively.
shows the five representative models for Mpro after clustering the trajectories depicted in colored cartoons. Additionally, the per-residue root-mean-square fluctuations (RMSF) in Å are plotted. The active site residues (H41 and C145) are marked on the RMSF curve. In addition to the protein termini, only one region (S46 - M49) shows moderate fluctuations (RMSF > 1.5 Å). This region is colored in red in the structures. The active site residues are away from this region and show low fluctuations (RMSF < 0.7 Å).

Figure 1. Molecular dynamics simulation analysis.

(A) The root-mean-square deviation (RMSD) (blue) and the radius of gyration (RoG) (red) versus the simulation time. (B) The per-residue root-mean-square fluctuations (RMSF) and the five representative structures of M\text{pro}. Active site residues (H41 and C145) are marked on the RMSF curve and the structures.
mean-square fluctuations (RMSF) and the five representative structures of Mpro. Active site residues (H41 and C145) are marked on the RMSF curve and the structures.

The bar graph of Figure 2A shows the average (out of five values) binding energy (in kcal/mol) against the Mpro of different SARS-CoV-2 conformations after MDS trajectory clustering. The error bars represent the standard deviation which was calculated by the Microsoft Excel formula \[ \text{Error Bar} = \frac{\sum (x_i - \overline{x})^2}{n-1} \]. Before the docking of the compounds, we tested the docking system by performing a redocking of O6K to the solved structure and we obtained a root-mean-square deviation of 0.92 Å (1806 fitted atoms). The positive controls O6K and N3 (putative inhibitors to Mpro found in the solved structures 6Y2G and 6LU7) are shown in red and orange, respectively, while the compounds 1, 5a-h, 8a-e, and 11a,b are in blue (Figure 2A). The best compound, 5h, is shown in green. The compound 5h has average binding energy \((-7.50 \pm 0.58\) kcal/mol) better than that of the positive controls O6K and N3 \((-7.36 \pm 0.34\) and \(-6.36 \pm 0.31\) kcal/mol). Despite the fact that the binding affinity value of 5h compound is not significantly different compared to the positive control, it is still a potential anti-SARS-CoV-2 Mpro compound that deserves further investigation.

Figure 2B shows the detailed interaction pattern between 5h and the Mpro. Five hydrophobic contacts are formed between 5h and the residues F140, E166(2), P168, and Q189 of Mpro. Additionally, the other tested compounds (except compound 1) present enhanced binding energies against Mpro (-6.38 ± 0.52 down to \(-7.18 \pm 0.29\) kcal/mol for 11b and 8e, respectively) compared to the positive control N3. This reflects their potential to be tightly bound to and might inhibit the Mpro of SARS-CoV-2.

Figure 2, Cont.
Figure 2. (A) Average binding energies (in kcal/mol) of the positive controls [O6K (red) and N3 (orange)] and compounds 1, 5a–h, 8a–e, and 11a,b (blue) docked into the active site residues of SARS-CoV-2 M\(^{\text{pro}}\). Error bars represent the standard deviations. The best compound in binding the SARS-CoV-2 M\(^{\text{pro}}\) (5h) is shown in green. (B) The docking complexes of compounds against SARS-CoV-2 M\(^{\text{pro}}\) are depicted by PyMOL software.
Table 1. The interaction pattern of the compounds (1, 5a–h, 8a–e, and 11a,b) and the positive control O6K against SARS-CoV-2 M<sub>pro</sub>.

| Compd | Binding Energy (kcal/mol) | H-Bonding or Halogen Bonds | Hydrophobic Interaction |
|-------|--------------------------|-----------------------------|------------------------|
|       |                          | Number | Residues Take Part in the Interaction | Number | Residues Take Part in the Interaction |
| O6K   | −7.4                     | 8      | S1, H41, G143, S144, C145, H164, and E166(2) | 4      | N142, M165, D187, and Q189 |
| N3    | −6.6                     | 2      | H164 and E166 | 3      | T25, T26, and P168 |
| 1     | −5.8                     | 2      | E166 and T190 |
| 5a    | −6.9                     | 4      | G143, S144, C145, and Q189 | 3      | M165, E166, and Q189 |
| 5b    | −6.7                     | 4      | G143, S144, C145, and Q192 | 2      | P39 and D187 |
| 5c    | −6.8                     | 2      | G143 and S144, R188 | 1      | Q189 |
| 5d    | −6.9                     | 2      | G143 and S144, R188 | 2      | N142 and Q189 |
| 5e    | −6.8                     | 2      | N142 and E166 | 6      | T25, N142, M165, E166, P168, and Q189 |
| 5f    | −6.6                     | 3      | G143, S144, and C145 | 4      | F140, M165, P168, and Q189 |
| 5g    | −6.9                     | 2      | G143 and S144, T190 | 5      | T25, Y118, M165, E166, and Q189 |
| 5h    | −7.5                     | 5      | F140, E166(2), P168, and Q189 |
| 8a    | −6.9                     | 3      | N142, E166, and L167 |
| 8b    | −7.2                     | 4      | N142, E166, L167, and P168 |
| 8c    | −7.0                     | 4      | N142, M165, E166, and L167 |
| 8d    | −7.0                     | 2      | N142 and E166 |
| 8e    | −7.1                     | 4      | N142, E166, and Q189(2) |
| 11a   | −6.5                     | 3      | G143, S144, and C145 | 2      | Q189(2) |
| 11b   | −6.3                     | 3      | G143, S144, and C145 | 2      | Q189(2) |

The binding affinities are listed among the number of H-bonds, halogen bonds, and hydrophobic contacts and the residues that take part in their formation in Table 1. Bold residues are the common residues interacting with the ligands, while the active site dyads are underlined. These residues are essential in the protease function as they lie within the active site pocket. When some small molecules block this pocket, it may interfere with the protease function (Figure 3A), which is yet to be verified experimentally. The best compound 5h (magenta sticks) is fitted in the active site pocket similar to the positive control O6K (green sticks) (Figure 3B). This indicates its possible usefulness as a SARS-CoV-2 M<sub>pro</sub> inhibitor. According to the SwissADME web tool (http://www.swissadme.ch/index.php) (accessed on 6 June 2016), compound 5h has poor solubility, has low gastrointestinal absorption, has a 674.84 g/mol molecular weight, 0.17 bioavailability score, and does not have adverse pharmacokinetics properties.
The binding affinities are listed among the number of H-bonds, halogen bonds, and hydrophobic contacts and the residues that take part in their formation in Table 1. Bold residues are the common residues interacting with the ligands, while the active site dyads are underlined. These residues are essential in the protease function as they lie within the active site pocket. When some small molecules block this pocket, it may interfere with the protease function (Figure 3A), which is yet to be verified experimentally. The best compound 5h (magenta sticks) is fitted in the active site pocket similar to the positive control O6K (green sticks) (Figure 3B). This indicates its possible usefulness as a SARS-CoV-2 Mpro inhibitor. According to the SwissADME web tool (http://www.swissadme.ch/index.php) (accessed on 6 June 2016), compound 5h has poor solubility, has low gastrointestinal absorption, has a 674.84 g/mol molecular weight, 0.17 bioavailability score, and does not have adverse pharmacokinetics properties.

Figure 3. (A) The most reported interacting residues of SARS-CoV-2 Mpro (green cartoon) with the ligands are represented using the solved structure (PDB ID: 6LU7). The active site dyads (H41 and C145) are represented by red sticks, while the yellow sticks represent the most reported interacting residues, N142, G143, S144, E166, and Q189 (underlined in Table 1). (B) The superposition of the Mpro (blue cartoon) is complexed with O6K (green sticks) and 5h (magenta sticks) for comparison. The active site pocket residues are labelled with its 1-letter codes.
We trust our simulation as the RMSD of our trajectory coincides with that of the large simulation trajectory found at the following link: (https://figshare.com/search?q=10.6084%2Ffm9.figshare.12009789) (accessed on 23 March 2020). Figure 4A shows the RMSD of our simulation trajectory (80 ns) in blue and the 1 microsecond trajectory in red. Additionally, we performed blind docking of the compounds utilizing AutoDock Vina implemented in PyRx software against both systems (after trajectory clustering) and found comparable results. The compounds show comparable results to positive controls, and 5h was the best based on the average binding affinities in both systems.

Figure 4. Cont.
Figure 4. Comparison between the 80 ns and the 1 microsecond trajectories. (A) The root-mean-square deviation versus the simulation time. (B) The superposition of the most abundant conformation over the 1 microsecond trajectory (red cartoon) with the five different conformations of the 80 ns trajectory (other colored cartoons). (C) The average binding energies were calculated using AutoDock Vina over PyRx software (blind) for both systems. Error bars represent the standard deviation.

3.1. Experimental

Melting points were measured on an Electrothermal IA 9000 series digital melting point apparatus. IR spectra were recorded on Pye Unicam SP 3300 and Shimadzu FTIR 8101 PC infrared spectrophotometers. NMR spectra were recorded on a Varian Mercury VX-300 NMR spectrometer operating at 300 MHz (1H-NMR) and 75 MHz (13C-NMR) and run in deuterated dimethylsulfoxide (DMSO-d6). Chemical shifts were related to that of the solvent. Mass spectra were recorded on a Shimadzu GCeMS-QP1000 EX mass spectrometer at 70 eV. Elemental analyses were measured by using a German made Elementar vario LIII CHNS analyzer.

Synthesis of 1,1′-(hexane-1,6-diyl)bis(3-phenylthiourea) (1).

Phenyl isothiocyanate (20 mmol) was added dropwise to a stirred solution of 1,6-diaminohexane (10 mmol) in 30 mL of DMF. The mixture was stirred at room temperature for 3 h and then added to ice/water mixture. A precipitate was formed and was recrystallized from ethanol as colorless crystals.

Yield (96%); m.p. 149–151° (Lit. m.p. 148–149° [35,36]); IR: ν 3344, 3222 (NH), 1560 (C=N), 1366 (C=S), 976 (C-N) cm⁻¹; ¹H-NMR δ = 1.24 (m, 4H, 2CH₂), 1.46 (m, 4H, 2CH₂), 3.38–3.41 (m, 4H, 2CH₂), 7.16–7.42 (m, 10H, Ar-H), 7.62 (br, s, 2H, 2NH), 9.44 (br s, 2H, 2NH) ppm; MS m/z (%): 386 (M⁺, 47). Anal. Calcd. for C₂₀H₂₆N₄S₂ (386.16): C, 62.14; H, 6.78; N, 14.49; S, 16.69. Found C, 62.04; H, 6.59; N, 14.33; S, 16.55%.

Synthesis of bis[1,3,4]thiadiazolimines and bis-thiazolimines.

A mixture of 1,1′-(hexane-1,6-diyl)bis(3-phenylthiourea) (1) (0.386 g, 1 mmol) and appropriate hydrazonyl halides 2a–h or α-haloketones 6a–e or 9a,b (2 mmol of each) in ethanol (20 mL) containing triethylamine (0.1 g, 1 mmol) was refluxed for 6–8 h. (monitored...
by TLC). The formed precipitate was isolated by filtration, washed with methanol, dried, and recrystallized from EtOH to give products 5a–h or 8a–e or 11a,b, respectively.

1,1′-[Hexane-1,6-diyl-bis(azaneylylidene)]bis[(4-phenyl-4,5-dihydro-1,3,4-thiadiazol-2-yl-5-ylidene)]bis(ethan-1-one) (5a).

Yellow crystals (70%); m.p. 173–175 °C; IR: ν 3024, 2932 (C-H), 1691 (C=O), 1623 (C=N) cm⁻¹; ¹H-NMR (DMSO-d₆): δ (ppm) 1.04–1.06 (m, 4H, -CH₂CH₂CH₂CH₂CH₂-), 1.16–1.21 (m, 4H, -CH₂CH₂CH₂CH₂CH₂-), 2.44 (s, 6H, 2CH₃), 3.37–3.42 (m, 4H, -CH₂CH₂CH₂CH₂CH₂-), 6.97–7.60 (m, 10H, Ar-H); ¹³C-NMR (DMSO-d₆): δ (ppm) 21.12 (CH-), 24.36 (CH₂), 26.81 (CH₂), 46.51 (CH₂-N), 124.51, 127.62, 129.21, 133.15, 145.61, 153.11 (Ar-C), 181.42 (C=O); MS m/z (%): 520 (M⁺, 71). Anal. Calcd. for C₂₆H₂₈N₀₂O₂S² (520.17): C, 59.98; H, 5.42; N, 16.14; S, 12.31. Found C, 59.80; H, 5.31; N, 16.07; S, 12.19%.

1,1′-[Hexane-1,6-diyl-bis(azaneylylidene)]bis[(4-p-tolyl)-4,5-dihydro-1,3,4-thiadiazole-2-yl-5-ylidene)]bis(ethan-1-one) (5b).

Yellow crystals (75%); m.p. 161–163 °C; IR: ν 3025, 2924 (C-H), 1707 (C=O), 1616 (C=N) cm⁻¹; ¹H-NMR (DMSO-d₆): δ 1.03–1.05 (m, 4H, -CH₂CH₂CH₂CH₂CH₂-), 1.19–1.52 (m, 4H, -CH₂CH₂CH₂CH₂CH₂-), 2.33 (s, 6H, 2Ar-CH₃), 2.44 (s, 6H, 2CH₃), 3.37–3.41 (m, 4H, -CH₂CH₂CH₂CH₂CH₂-), 6.97–7.54 (m, 8H, Ar-H); ¹³C-NMR (DMSO-d₆): δ (ppm) 21.19 (CH₂), 23.41 (CH₃), 24.28 (CH₃), 26.83 (CH₃), 46.72 (CH₂-N), 124.51, 127.55, 129.74, 132.95, 145.84, 153.17 (Ar-C), 180.81 (C=O); MS m/z (%): 548 (M⁺, 46). Anal. Calcd. for C₂₆H₂₈N₀₂O₂S₂ (548.20): C, 61.29; H, 5.88; N, 15.32; S, 11.69. Found C, 61.16; H, 5.93; N, 15.18; S, 11.75%.

1,1′-[Hexane-1,6-diyl-bis(azaneylylidene)]bis[(4-(4-chlorophenyl)-4,5-dihydro-1,3,4-thiadiazole-2-yl-5-ylidene)]bis(ethan-1-one) (5c).

Yellow crystals (77%); m.p. 180–182 °C; IR: ν 3022, 2931 (C-H), 1701 (C=O), 1619 (C=N) cm⁻¹; ¹H-NMR (DMSO-d₆): δ 1.17–1.21 (m, 4H, -CH₂CH₂CH₂CH₂CH₂-), 1.51–1.59 (m, 4H, -CH₂CH₂CH₂CH₂CH₂-), 2.49 (s, 6H, 2CH₃), 3.45–3.47 (m, 4H, -CH₂CH₂CH₂CH₂CH₂-), 6.97–7.64 (m, 8H, Ar-H); ¹³C-NMR (DMSO-d₆): δ (ppm) 21.18 (CH₂), 24.34 (CH₃), 26.78 (CH₃), 45.81 (CH₂-N), 122.91, 125.62, 129.13, 134.11, 146.61, 153.18 (Ar-C), 183.41 (C=O); MS m/z (%): 590 (M⁺ +2, 11), 588 (M⁺, 38). Anal. Calcd. for C₂₆H₂₆Cl₂N₀₂O₂S₂ (588.09): C, 52.97; H, 4.45; N, 14.26; S, 10.88. Found C, 52.83; H, 4.41; N, 14.11; S, 11.02%.

1,1′-[Hexane-1,6-diyl-bis(azaneylylidene)]bis[(4-(2,4-dichlorophenyl)-4,5-dihydro-1,3,4-thiadiazole-2-yl-5-ylidene)]bis(ethan-1-one) (5d).

Yellow crystals (77%); m.p. 179–181 °C; IR: ν 3028, 2921 (C-H), 1704 (C=O), 1617 (C=N) cm⁻¹; ¹H-NMR (DMSO-d₆): δ 1.17–1.22 (m, 4H, -CH₂CH₂CH₂CH₂CH₂-), 1.51–1.58 (m, 4H, -CH₂CH₂CH₂CH₂CH₂-), 2.43 (s, 6H, 2CH₃), 3.41–3.47 (m, 4H, -CH₂CH₂CH₂CH₂CH₂-), 6.96–7.68 (m, 6H, Ar-H); ¹³C-NMR (DMSO-d₆): δ (ppm) 21.88 (CH₂), 25.11 (CH₃), 28.80 (CH₂), 45.94 (CH₂-N), 123.51, 125.62, 126.21, 127.15, 131.61, 132.54, 141.41, 154.11 (Ar-C), 184.42 (C=O); MS m/z (%): 660 (M⁺ +4, 4), 658 (M⁺ +2, 14), 656 (M⁺, 35). Anal. Calcd. for C₂₆H₂₄Cl₄N₀₂O₂S₂ (656.02): C, 47.43; H, 3.67; N, 12.76; S, 9.74. Found C, 47.37; H, 3.54; N, 12.66; S, 9.61%.

Diethyl 5,5′-[hexane-1,6-diyl-bis(azaneylylidene)]bis[(4-o-tolyl)-4,5-dihydro-1,3,4-thiadiazole-2-carboxylate] (5e).

Yellow crystals (72%); m.p. 192–194 °C; IR: ν 3028, 2927 (C-H), 1728 (C=O), 1612 (C=N) cm⁻¹; ¹H-NMR (DMSO-d₆): δ 1.19–1.20 (t, 6H, 2CH₃CH₂), 1.23–1.35 (m, 4H, -CH₂CH₂CH₂CH₂CH₂-), 1.55–1.58 (m, 4H, -CH₂CH₂CH₂CH₂CH₂-), 2.34 (s, 6H, 2Ar-CH₃), 3.45–3.47 (m, 4H, -CH₂CH₂CH₂CH₂CH₂-), 4.32–4.39 (q, 4H, 2CH₂CH₃), 6.97–7.42 (m, 8H, Ar-H); ¹³C-NMR (DMSO-d₆): δ (ppm) 14.84 (CH₃-CH₂-), 21.19 (CH₂), 23.11 (Ar-CH₃), 26.77 (CH₂), 46.72 (CH₂-N), 56.17 (CH₃-CH₂-), 120.51, 123.55, 126.74, 129.42, 132.11, 133.64, 142.84, 154.17 (Ar-CH), 171.81 (C=O); MS m/z (%): 608 (M⁺, 19). Anal.
Diethyl 5,5′-[hexane-1,6-diyl-bis(azaneylidenede)-bis[4-(dichlorophenyl)-4,5-dihydro-1,3,4-thiadiazole-2-carboxylate] (5f).

Yellowish brown crystals (76%); m.p. 177–179 °C; IR (KBr): ν 3039, 2927 (CH), 1731 (C=O), 1601 (C=N) cm⁻¹; ¹H-NMR (DMSO-d₆): δ 1.18–1.21 (t, 6H, 2CH₂CH₃), 1.24–1.33 (m, 4H, -CH₂CH₂CH₂CH₂CH₂CH₂), 1.55–1.67 (m, 4H, -CH₂CH₂CH₂CH₂CH₂CH₂), 3.45–3.47 (m, 4H, -CH₂CH₂CH₂CH₂CH₂CH₂), 3.42–3.49 (q, 4H, 2CH₂CH₃), 6.99–7.44 (m, 8H, Ar-H); ¹³C-NMR (DMSO-d₆): δ (ppm) 14.88 (CH₃-CH₂-O), 21.17 (CH₂), 26.77 (CH₂), 46.76 (CH₂-N), 56.52 (CH₂-CH₂-O), 121.51, 126.74, 129.11, 135.54, 148.84, 155.17 (Ar-C), 170.11 (C=O); MS m/z (%): 478 (M⁺ +2, 11), 650 (M⁺ +2, 6), 648 (M⁺, 14). Anal. Calcd. for C₂₉H₃₀Cl₂N₄O₄S₂ (648.11): C, 51.77; H, 4.66; N, 12.94; S, 9.87. Found C, 51.59; H, 4.72; N, 13.02; S, 10.05%.

Diethyl 5,5′-[hexane-1,6-diyl-bis(azaneylidenede)-bis[4-(2,4-dichlorophenyl)-4,5-dihydro-1,3,4-thiadiazole-2-carboxylate] (5g).

Brown solid (78%); m.p. 192–194 °C; IR (KBr): ν 3064, 2927 (CH), 1728 (C=O), 1603 (C=N) cm⁻¹; ¹H-NMR (DMSO-d₆): δ 1.18–1.23 (t, 6H, 2CH₂CH₃), 1.28–1.36 (m, 4H, -CH₂CH₂CH₂CH₂CH₂CH₂), 1.55–1.64 (m, 4H, -CH₂CH₂CH₂CH₂CH₂CH₂), 3.43–3.46 (m, 4H, -CH₂CH₂CH₂CH₂CH₂CH₂), 3.47–3.49 (q, 4H, 2CH₂CH₃), 6.86–7.81 (m, 6H, Ar-H); ¹³C-NMR (DMSO-d₆): δ (ppm) 14.11 (CH₃-CH₂-O), 21.19 (CH₂), 26.68 (CH₂), 46.98 (CH₂-N), 56.64 (CH₂-CH₂-O), 123.51, 127.74, 129.11, 131.54, 133.89, 141.84, 148.17, 154.17 (Ar-C), 170.13 (C=O); MS m/z (%): 720 (M⁺ +4, 4), 718 (M⁺ +2, 14), 716 (M⁺, 35). Anal. Calcd. for C₂₉H₂₅Cl₂N₄O₄S₂ (716.04): C, 51.77; H, 4.66; N, 11.70; S, 8.92. Found C, 51.71; H, 4.62; N, 11.57; S, 8.79%.

5,5′-[Hexane-1,6-diyl-bis(azaneylidenede)]bis[N₄-diphenyl-4,5-dihydro-1,3,4-thiadiazole-2-carboxamide] (5h).

Yellow solid (75%); m.p. 188–190 °C; IR (KBr): ν 3271 (NH), 3025, 2924 (C-H), 1644 (C=O), 1602 (C=N) cm⁻¹; ¹H-NMR (DMSO-d₆): δ (ppm) 1.03–1.05 (m, 4H, -CH₂CH₂CH₂CH₂CH₂CH₂), 1.19–1.23 (m, 4H, -CH₂CH₂CH₂CH₂CH₂CH₂), 3.37–3.42 (m, 4H, -CH₂CH₂CH₂CH₂CH₂CH₂), 6.97–7.54 (m, 20H, Ar-H), 10.42 (s, 2H, 2NH); ¹³C-NMR (DMSO-d₆): δ (ppm) 21.08 (CH₃), 25.81 (CH₂), 44.51 (CH₂-N), 121.51, 123.62, 126.21, 127.71, 128.15, 131.55, 133.57, 137.64, 146.61, 155.11 (Ar-C), 161.42 (C=O); MS m/z (%): 674 (M⁺, 38). Anal. Calcd. for C₃₆H₃₄N₄O₄S₂ (674.22): C, 64.07; H, 5.08; N, 16.60; S, 9.50. Found C, 64.12; H, 5.03; N, 16.42; S, 9.39%.

N,N′-[Hexane-1,6-diyl]bis[3,4-diphenylthiazol-(2H)-imine] (8a).

Yellow solid (76%); m.p. 171–173 °C; IR (KBr): ν 2924 (C-H), 1578 (C=N) cm⁻¹; ¹H-NMR (DMSO-d₆): δ (ppm) 1.02–1.05 (m, 4H, -CH₂CH₂CH₂CH₂CH₂CH₂), 1.19–1.23 (m, 4H, -CH₂CH₂CH₂CH₂CH₂CH₂), 3.43–3.55 (m, 4H, -CH₂CH₂CH₂CH₂CH₂CH₂), 6.99–7.95 (m, 22H, Ar-H & thiazole-H); ¹³C-NMR (DMSO-d₆): δ (ppm) 21.11 (CH₃), 24.81 (CH₂), 46.31 (CH₂-N), 122.51, 124.62, 125.21, 127.71, 128.15, 128.94, 129.55, 131.27, 134.57, 137.64, 158.11 (Ar-C); MS m/z (%): 586 (M⁺, 18). Anal. Calcd. for C₃₆H₃₄N₄S₂ (586.22): C, 73.69; H, 5.84; N, 9.55; S, 10.93. Found C, 73.58; H, 5.69; N, 9.38; S, 11.06%.

N,N′-[Hexane-1,6-diyl]bis[3-phenyl-4-(p-tolyl)thiazol-(2H)-imine] (8b).

Yellow solid (79%); m.p. 169–171 °C; IR (KBr): ν 2934 (C=H), 1599 (C=N) cm⁻¹; ¹H-NMR (DMSO-d₆): δ (ppm) 1.02–1.06 (m, 4H, -CH₂CH₂CH₂CH₂CH₂CH₂), 1.19–1.38 (m, 4H, -CH₂CH₂CH₂CH₂CH₂CH₂), 2.35 (s, 6H, 2Ar-CH₃), 3.34–3.51 (m, 4H, -CH₂CH₂CH₂CH₂CH₂CH₂), 6.95–7.84 (m, 20H, Ar-H & thiazole-H); ¹³C-NMR (DMSO-d₆): δ (ppm) 21.19 (CH₂), 23.31 (CH₃), 26.58 (CH₂), 46.11 (CH₂-N), 122.42, 123.58, 124.11, 125.51, 126.34, 127.52, 128.11, 129.74, 130.95, 135.84, 148.17 (Ar-C); MS m/z (%): 614 (M⁺, 22). Anal. Calcd. for C₃₈H₃₈N₄S₂ (614.25): C, 74.23; H, 6.23; N, 9.11; S, 10.43. Found C, 74.14; H, 6.19; N, 9.00; S, 10.51%.
N,N′-(Hexane-1,6-diyl)bis[4-(4-chlorophenyl)-3-phenylthiazol-2(3H)-imine] (8c).

Yellow solid (82%); m.p. 201–203 °C; IR (KBr): ν 2931 (C-H), 1602 (C=N) cm⁻¹; ¹H-NMR (DMSO-d₆): δ 1.02–1.05 (m, 4H, -CH₂CH₂CH₂CH₂CH₂CH₂), 1.42–1.51 (m, 4H, -CH₂CH₂CH₂CH₂CH₂CH₂), 3.29–3.32 (m, 4H, -CH₂CH₂CH₂CH₂CH₂CH₂), 6.88–7.64 (m, 20H, Ar-H & thiazole-H); ¹³C-NMR (DMSO-d₆): δ (ppm) 21.15 (CH₂), 26.73 (CH₂), 46.08 (CH₂-N), 122.93, 123.45, 124.11, 125.42, 126.51, 127.11, 128.46, 129.13, 133.11, 146.65, 154.18 (Ar-C); MS m/z (%): 656 (M⁺ +2, 8), 654 (M⁺, 25). Anal. Calcd. for C₃₆H₃₂Cl₂N₄S₂ (654.14): C, 65.94; H, 4.92; N, 8.54; S, 9.78. Found C, 65.83; H, 4.80; N, 8.39; S, 9.64%.

N,N′-(Hexane-1,6-diyl)bis[4-(4-bromophenyl)-3-phenylthiazol-2(3H)-imine] (8d).

Yellow solid (79%); m.p. 211–213 °C; IR (KBr): ν 2931 (C-H), 1602 (C=N) cm⁻¹; ¹H-NMR (DMSO-d₆): δ 1.04–1.07 (m, 4H, -CH₂CH₂CH₂CH₂CH₂CH₂), 1.31–1.41 (m, 4H, -CH₂CH₂CH₂CH₂CH₂CH₂), 3.46–3.67 (m, 4H, -CH₂CH₂CH₂CH₂CH₂CH₂), 6.85–7.65 (m, 20H, Ar-H & thiazole-H); ¹³C-NMR (DMSO-d₆): δ (ppm) 21.11 (CH₂), 26.71 (CH₂), 45.88 (CH₂-N), 122.91, 123.35, 124.09, 125.12, 126.38, 127.11, 128.16, 129.13, 132.89, 145.63, 154.12 (Ar-C); MS m/z (%): 744 (M⁺ +2, 10), 742 (M⁺, 26). Anal. Calcd. for C₃₆H₃₂Br₂N₄S₂ (742.04): C, 58.07; H, 4.33; N, 7.52; S, 8.61. Found C, 58.19; H, 4.24; N, 7.39; S, 8.72%.

N,N′-(Hexane-1,6-diyl)bis[4-(4-nitrophenyl)-3-phenylthiazol-2(3H)-imine] (8e).

Yellow solid (77%); m.p. 193–195 °C; IR (KBr): ν 2928 (C-H), 1602 (C=N) cm⁻¹; ¹H-NMR (DMSO-d₆): δ 1.04–1.08 (m, 4H, -CH₂CH₂CH₂CH₂CH₂CH₂), 1.36–1.52 (m, 4H, -CH₂CH₂CH₂CH₂CH₂CH₂), 3.36–3.42 (m, 4H, -CH₂CH₂CH₂CH₂CH₂CH₂), 6.88–8.34 (m, 20H, Ar-H & thiazole-H); ¹³C-NMR (DMSO-d₆): δ (ppm) 21.54 (CH₂), 26.92 (CH₂), 46.18 (CH₂-N), 122.92, 123.39, 125.09, 126.12, 127.38, 128.11, 129.16, 134.13, 143.15, 147.61, 158.12 (Ar-C); MS m/z (%): 676 (M⁺, 38). Anal. Calcd. for C₃₆H₃₂N₆O₄S₂ (676.19): C, 63.89; H, 4.77; N, 12.42; S, 9.47. Found C, 63.75; H, 4.58; N, 12.30; S, 9.57%.

1,1′-[Hexane-1,6-diyli[bis(azaneylidene)]bis[4-methyl-3-phenyl-2,3-dihydrothiazole-5-y1-2-yldenedebis(ethan-1-one)] (11a).

Yellow solid (72%); m.p. 185–187 °C; IR (KBr): ν 2930 (C-H), 1684 (C=O), 1600 (C=N) cm⁻¹; ¹H-NMR (DMSO-d₆): δ 1.03–1.05 (m, 4H, -CH₂CH₂CH₂CH₂CH₂CH₂), 1.21–1.43 (m, 4H, -CH₂CH₂CH₂CH₂CH₂CH₂), 2.28 (s, 6H, 2COCH₃), 2.55 (s, 6H, 2 thiazole-CH₃), 3.30–3.41 (m, 4H, -CH₂CH₂CH₂CH₂CH₂CH₂), 6.93–7.35 (m, 10H, Ar-H); ¹³C-NMR (DMSO-d₆): δ (ppm) 16.85 (thiazole-CH₂), 21.12 (CH₂), 24.33 (COCH₃), 26.83 (CH₂), 46.54 (CH₂-N), 118.12, 122.51, 126.62, 129.21, 141.15, 144.61, 154.11 (Ar-C), 181.48 (C=O); MS m/z (%): 546 (M⁺, 20). Anal. Calcd. for C₃₆H₃₄N₄O₄S₂ (546.21): C, 65.90; H, 6.27; N, 10.25; S, 11.73. Found C, 65.97; H, 6.09; N, 10.16; S, 11.87%.

Diethyl[2,2′-[hexane-1,6-diyl-bis(azaneylidene)]-bis[4-methyl-3-phenyl-2,3-dihydrothiazole-5-carboxylate] (11b).

Yellow solid (81%); m.p. 207–209 °C; IR (KBr): ν 2927 (C-H), 1708 (C=O), 1601 (C=N) cm⁻¹; ¹H-NMR (DMSO-d₆): δ 1.03–1.05 (m, 4H, -CH₂CH₂CH₂CH₂CH₂CH₂), 1.16–1.18 (t, 6H, 2CH₂CH₃), 1.41–1.48 (m, 4H, -CH₂CH₂CH₂CH₂CH₂CH₂), 2.57 (s, 6H, 2 thiazole-CH₃), 3.85–3.92 (m, 4H, -CH₂CH₂CH₂CH₂CH₂CH₂), 4.12–4.16 (q, 4H, 2CH₂CH₃), 6.89–7.34 (m, 10H, Ar-H); ¹³C-NMR (DMSO-d₆): δ (ppm) 14.24 (CH₂-C=O), 17.25 (thiazole-CH₂), 21.18 (CH₂), 26.74 (CH₂), 46.62 (CH₂-N), 56.95 (CH₃CH₂O), 122.51, 126.55, 128.74, 129.4, 143.11, 153.54, 158.17 (Ar-C), 170.12 (C=O); MS m/z (%): 606 (M⁺, 16). Anal. Calcd. for C₃₂H₃₆N₂O₄S₂ (606.23): C, 63.34; H, 6.31; N, 9.23; S, 10.57. Found C, 63.25 H, 6.20; N, 9.18; S, 10.48%.

3.2. Molecular Docking

Compounds are drawn using the Avogadro software 1.2.0, where the universal force field (UFF) was utilized to optimize the structures [37,38]. The docking was performed using AutoDock Vina software using the flexible ligand in the flexible active site (H41
and C145) protocol [39,40]. SARS-CoV-2 main protease \( \text{M}^{\text{pro}} \) dimer structure (PDB ID: 6Y2G) was downloaded from the protein data bank (https://www.rcsb.org/) (accessed on 20 March 2020) [27]. O6K, \( \alpha \)-ketoamide inhibitor, is the positive control molecule that was solved in the \( \text{M}^{\text{pro}} \) structure and was used to examine the affinity of the compounds 1, 5a–h, 8a–e, and 11a,b to the \( \text{M}^{\text{pro}} \) active site. O6K is a covalently bound ligand, but we redock it to the solved structure in a non-bonded fashion, and it gives a root-mean-square difference of 0.966 Å. Additionally, the peptidyl Michael acceptor, N3, found in the solved structure of Mpro (PDB ID: 6LU7) is also used as a positive control for comparison [30]. The \( \text{M}^{\text{pro}} \) dimer was subjected to molecular dynamics simulation (MDS) which ran for 80 nanoseconds, as reported [41] before the docking study. The MDS was conducted on the WEBGRO macromolecular simulation utilizing GROMACS software and CHARMM27 force field [42,43]. A minimization for 10,000 steps of the conjugate gradient is performed before the MDS run. TIP4P water model was used with a constant number of atoms, volume, and temperature (NVT) ensemble in cubic periodic boundary conditions. \( \text{Na}^+ \) and \( \text{Cl}^- \) were added to the system for the salt concentration of 154 mM, while the temperature and pressure were adjusted to be 310 K and 1 atm, respectively, to resemble physiological conditions. Clustering of the trajectories was performed using the UCSF Chimera 1.14 software [44]. A representative structure from each cluster was used when testing the binding affinity using the AutoDock Vina software [39,45].

The search box was adjusted to cover the active site dyad (H41 and C145) with dimensions of 30 Å × 30 Å × 30 Å centered at (25.2, 47.3, 38.4) Å. Protein–ligand interaction profiler (PLIP) webserver (https://plip-tool.biotec.tu-dresden.de/plip-web/plip/index) (accessed on 5 May 2021) was utilized to check the binding modes and the data are tabulated and then represented using PyMOL software 2.0.4 in the results section [46–48]. In the current study, we used an exhaustiveness value of 100. This is due to the many rotatable bonds we have in some ligands.

4. Conclusions

The present study disclosed the preparation of 1,1′-(hexane-1,6-diyl)bis(3-phenylthiourea) which was employed as a key intermediate for the synthesis of a new series of \( \text{bis} \)-[1,3,4]thiadiazolimines, and \( \text{bis} \)-thiazolimines, with an alkyl linker, through its reaction with various hydrazonoyl halides or \( \alpha \)-haloketones, respectively. The newly synthesized derivatives’ structures were confirmed by elemental analysis and spectral data. Docking studies were applied to test the binding affinity of the synthesized products against the \( \text{M}^{\text{pro}} \) of SARS-CoV-2. The study results showed that compound 5h is the best one as it has average binding energy \((-7.50 \pm 0.58 \text{ kcal/mol})\) better than that of the positive controls, O6K and N3 \((-7.36 \pm 0.34 \text{ kcal/mol})\). Additionally, the docking poses (H-bonds and hydrophobic contacts) of the tested compounds against the \( \text{M}^{\text{pro}} \) using the PLIP web server were analyzed. This work paves the way for the design and synthesis of \( \text{bis} \)-thiadiazoles and \( \text{bis} \)-thiazoles-based libraries, which could lead to the innovation of efficient treatment against SARS-CoV-2 main protease (\( \text{M}^{\text{pro}} \)).

**Author Contributions:** S.M.G., S.M.R., M.H.A., T.Z.A., H.M.A.-a., A.A.N., A.M.E. and A.A.E.: Supervision, investigation, methodology, resources, formal analysis, data curation, funding acquisition, writing—original draft, writing—review and editing. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** The data presented in this study are available on request from corresponding author.

**Conflicts of Interest:** The authors declare no conflict of interest.
References

1. Gao, Z.; Xu, Y.; Sun, C.; Wang, X.; Guo, Y.; Qiu, S.; Ma, K. A systematic review of asymptomatic infections with COVID-19. J. Microbiol. Immunol. Infect. 2021, 54, 12–16. [CrossRef] [PubMed]

2. Yüce, M.; Filiztekin, E.; Özayka, K.G. COVID-19 diagnosis—A review of current methods. Biosens. Bioelectron. 2021, 172, 112752. [CrossRef]

3. Li, Y.; Tenchov, R.; Smoot, J.; Liu, C.; Watkins, S.; Zhou, Q. A Comprehensive Review of the Global Efforts on COVID-19 Vaccine Development. ACS Cent. Sci. 2021, 7, 512–533. [CrossRef]

4. Noor, R. A Review on the Effectivity of the Current COVID-19 Drugs and Vaccines: Are They Really Working Against the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants? Curr. Clin. Microbiol. Rep. 2021, 8, 186–193. [CrossRef] [PubMed]

5. El-Enany, W.A.M.A.; Gomha, S.M.; El-Ziaty, A.K.; Hussein, W.; Abdulla, M.M.; Hassan, S.A.; Sallam, H.A.; Ali, R.S. Synthesis and molecular docking of some new bis-thiadiazoles as antihypertensive α-blocking agents. Synth. Commun. 2019, 50, 85–96. [CrossRef]

6. El-Enany, W.A.M.A.; Gomha, S.M.; El-Ziaty, A.K.; Hussein, W.; Sallam, H.A.; Ali, R.S.; El-Ziaty, A.K. Synthesis and Biological Evaluation of Some Novel bis-Thiadiazoles as Antimicrobial and Antitumor Agents. Polycycl. Aromat. Compd. 2021, 41, 2071–2082. [CrossRef]

7. Gomha, S.M.; Muhammad, Z.A.; Al-Hussain, S.A.; Zaki, M.E.A.; Abdel-aziz, H.M. Synthesis, Characterization and antimicrobial evaluation of some new 1,4-dihydropyridine hybrid with 1,3,4-thiadiazole. Polycycl. Aromat. Compd. 2022, 42, 1697–1709. [CrossRef]

8. Gomha, S.M.; El-Gindy, M.S.; Muhammad, Z.A.; Abdelhamid, A.O.; Abdel-Aziz, M.M. Utility of Bis-Hydr azonoyl Chlorides as Precursors for Synthesis of New Functionalized bis-Thiadiazoles as Potent Antimicrobial Agents. J. Heterocycl. Chem. 2018, 55, 844–851. [CrossRef]

9. Gomha, S.M.; Kheder, N.A.; Abdelhamid, A.O.; Makbhot, Y.N. One Pot Single Step Synthesis and Biological Evaluation of Some Novel Bis(1,3,4-thiadiazole) Derivatives as Potential Cytotoxic Agents. Molecules 2016, 21, 1532. [CrossRef] [PubMed]

10. Gomha, S.M.; Muhammad, Z.A.; El-Reedy, A.A.M. Intramolecular ring transformation of bis-oxadiazoles to bis-thiadiazoles and investigation of their anticancer activities. J. Heterocycl. Chem. 2018, 55, 2360–2367. [CrossRef]

11. Muhammad, Z.A.; Masaret, G.; Amin, M.A.; Abdallah, M.A.; Farghaly, T.A. Anti-inflammatory, Analgesic and Anti-ulcerogenic Activities of Novel bis-thiadiazoles, bis-thiazoles and bis-formazanes. Med. Chem. 2017, 13, 226–238. [CrossRef]

12. Dawood, K.M.; Eldebss, T.M.A.; El-Zahabi, H.S.A.; Yousef, M.H. Synthesis and antiviral activity of some new bis-1,3-thiole derivatives. Eur. J. Med. Chem. 2015, 102, 266–276. [CrossRef]

13. Kassab, R.M.; Gomha, S.M.; Al-Hussain, S.A.; Abo Dena, A.S.; Abdel-Aziz, M.M.; Zaki, M.E.A.; Muhammad, Z.A. Synthesis in-silico simulation of some new bis-thiazole derivatives and their preliminary antimicrobial profile: Investigation of hydrazonoyl chloride addition to hydroxy-functionalized bis-carbazones. Arab. J. Chem. 2021, 14, 103396. [CrossRef]

14. Mahmoud, H.K.; Abbas, A.A.; Gomha, S.M. Synthesis, antimicrobial evaluation and molecular docking of new functionalized bis(1,3,4-thiadiazole) and bis(thiazole) derivatives. Polycycl. Aromat. Compd. 2021, 41, 2029–2041. [CrossRef]

15. Al-Omair, M.A.; Sayed, A.R.; Youssef, M. Synthesis and Biological Evaluation of Bisthiazoles and Polythiazoles. Molecules 2018, 23, 1133. [CrossRef]

16. Gomha, S.M.; Badrey, M.G.; Edrees, M.M. Heterocyclization of a bis-thiosemicarbazone of 2,5-diacyl-3,4-disubstituted-thieno[2,3-b]thiophene bis-1,4-phenylene-bis-thiazole and bis-1,3,4-thiadiazoles as anti-breast cancer agents. J. Chem. Res. 2016, 40, 120–125. [CrossRef]

17. Gomha, S.M.; Edrees, M.M.; Altalbawy, F.M.A. Synthesis and characterization of some new bis-pyrazolyl-thiazoles incorporating the thiole moiety as potent anti-tumor agents. Inter. J. Mol. Sci. 2016, 17, 1499. [CrossRef]

18. Gomha, S.M.; El-Hashash, M.A.; Edrees, M.M.; El-Arab, E.E. Synthesis, characterization and molecular docking of novel bis-thiazolyl thienothiophene derivatives as promising cytotoxic antitumor drug. J. Heterocycl. Chem. 2017, 54, 2686–2695. [CrossRef]

19. Alshabahanah, L.A.; Gomha, S.M.; Al-Mutabagani, L.A.; Abolibda, T.Z.; Abd El-Ghany, N.A.; El-Enany, W.A.M.A.; El-Ziaty, A.K.; Ali, R.S.; Mohamed, N.A. Cross-linked chitosan/multi-walled carbon nanotubes composite as ecofriendly biocatalyst for synthesis of some composite as ecofriendly biocatalyst for synthesis of some novel benzil bis-thiazoles. Polymers 2021, 13, 1728. [CrossRef]

20. Altamimi, M.A.; Hussain, A.; Alshehri, S.; Imam, S.S.; Alnami, A.; Bari, A. Novel hemocompatible imine compounds as alternatives for antimicrobial therapy in pharmaceutical application. Processes 2020, 8, 1476. [CrossRef]

21. Bashiri, M.; Jarrahpour, A.; Rastegari, B.; Iraj, A.; Irajie, C.; Amighorfan, Z.; Malek-Hosseini, S.; Motamedifar, M.; Haddadi, M.; Zomorodian, K.; et al. Synthesis and evaluation of biological activities of tripepol monomers and β-lactams to the 1,3,5-triazine nucleus. Monatsh. Chem. 2020, 151, 821–835. [CrossRef]

22. da Silva, E.T.; Araújo, A.S.; Moraes, A.M.; de Souza, L.A.; Lourenço, M.C.S.; de Souza, M.V.N.; Wardell, J.L.; Wardell, S.M.S.V. Synthesis and Biological Activities of Camphor Hydrazone and Imine Derivatives. Sci. Pharm. 2016, 84, 467. [CrossRef] [PubMed]

23. Saktinathan, S.P.; Suresh, R.; Kamalakkanann, D.; Mala, V.; Sathiyamoorthi, K.; Vanangamudi, G.; Thirunarayanan, G. Microwave assisted synthesis, spectral correlation and antimicrobial Evaluation of some aryl imines. J. Chil. Chem. Soc. 2018, 63, 3918–3923. [CrossRef]
24. Gomha, S.M.; Edrees, M.M.; Muhammad, Z.A.; El-Reedy, A.A.M. 5-(Thiophen-2-yl)-1,3,4-thiadiazole derivatives: Synthesis, molecular docking and in-vitro cytotoxicity evaluation as potential anticancer agents. Drug Des. Dev. Ther. 2018, 12, 1511–1523. [CrossRef]

25. Alshababah, L.A.; Al-Mutabagani, L.A.; Gomha, S.M.; Ahmed, H.A. Three-component synthesis of some new coumarin derivatives as anti-cancer agents. Front. Chem. 2022, 9, 762248. [CrossRef]

26. Abu-Melha, S.; Edrees, M.M.; Said, M.A.; Riyad, S.M.; Al-Kaff, N.S.; Gomha, S.M. Potential COVID-19 Drug Candidates Based on Diazinyl-Thiazol-Imine Moieties: Synthesis and Greener Pastures Biological Study. Molecules 2022, 27, 488. [CrossRef]

27. Zhang, L.; Lin, D.; Sun, X.; Curth, U.; Drosten, C.; Sauerhering, L.; Becker, S.; Rox, K.; Hilgenfeld, R. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors. Science 2020, 368, 409–412. [CrossRef]

28. Citarella, A.; Scala, A.; Piperno, A.; Micale, N. SARS-CoV-2 M(pro): A Potential Target for Peptidomimetics and Small-Molecule Inhibitors. Biomolecules 2021, 11, 607. [CrossRef]

29. Goyal, B.; Goyal, D. Targeting the Dimerization of the Main Protease of Coronavirus: A Potential Broad-Spectrum Therapeutic Strategy. ACS Comb. Sci. 2020, 22, 297–305. [CrossRef]

30. Jin, Z.; Du, X.; Deng, Y.; Liu, M.; Zhao, Y.; Zhang, B.; Li, X.; Zhang, L.; Peng, C.; et al. Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature 2020, 582, 289–293. [CrossRef]

31. Macip, G.; Garcia-Segovia, P.; Mestres-Truyol, J.; Saldivar-Espinoza, B.; Pujadas, G.; Garcia-Vallvé, S. A Review of the Current Landscape of SARS-CoV-2 Main Protease Inhibitors: Have We Hit the Bullseye Yet? Int. J. Mol. Sci. 2021, 23, 259. [CrossRef] [PubMed]

32. Abu-Melha, S.; Edrees, M.M.; Riyadh, S.M.; Abdelaziz, M.R.; Elfiky, A.A.; Gomha, S.M. Clean Grinding Technique: A Facile Synthesis and In Silico Antiviral Activity of Hydrazones, Pyrazoles, and Pyrazines Bearing Thiazole Moiety against SARS-CoV-2 Main Protease (Mpro). Molecules 2020, 25, 4565. [CrossRef]

33. Burki, T.K. The role of antiviral treatment in the COVID-19 pandemic. Lancet Respir. Med. 2022, 10, e18. [CrossRef]

34. Owen, D.R.; Allerton, C.M.N.; Anderson, A.S.; Aschenbrenner, L.; Avery, M.; Berritt, S.; Boras, B.; Cardin, R.D.; Carlo, A.; Coffman, K.J.; et al. An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19. Science 2021, 374, 1586–1593. [CrossRef]

35. Doupp, D.; Hassan, A.A. Thermolysis of N,N′-ω-alkanediy1-bis[n′-organylthiourea] derivatives. J. Heterocycl. Chem. 2006, 43, 593–598. [CrossRef]

36. Stoutland, O.; Helgen, L.; Agre, C.L. Reactions of diamines with isocyanates and isothiocyanates. J. Org. Chem. 1959, 24, 818–820. [CrossRef]

37. Hanwell, M.D.; Curitis, D.E.; Loniem, D.C.; Vandermeersch, T.; Zurek, E.; Hutchison, G.R. Avogadro: An advanced semantic chemical editor, visualization, and analysis platform. J. Cheminform. 2012, 4, 17–30. [CrossRef]

38. Rappé, A.K.; Casewitt, C.J.; Colwell, K.S.; Goddard, W.A.; Skiff, W.M. UFF, a full periodic table force field for molecular mechanics and molecular dynamics simulations. J. Am. Chem. Soc. 1992, 114, 10024–10035. [CrossRef]

39. Trott, O.; Olson, A.J. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 2010, 31, 455–461. [CrossRef]

40. Morris, G.M.; Huey, R.; Lindstrom, W.; Sanner, M.F.; Belew, R.K.; Goodsell, D.S.; Olson, A.J. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J. Comput. Chem. 2009, 30, 2785–2791. [CrossRef]

41. Elgohary, A.M.; Elfiky, A.A.; Pereira, F.; Abd El-Aziz, T.M.; Sobeh, M.; Arafa, R.K.; El-Demerdash, A. Investigating the Structure-Activity Relationship of Marine Polycyclic Batzelladine Alkaloids as Promising Inhibitors for SARS-CoV-2 Main Protease (Mpro). ChemRxtx 2022. [CrossRef]

42. Bekker, H.; Berendsen, H.J.; Dijkstra, E.J.; Achterop, S.; Vondrumen, R.; Vanderspol, D.; Sijbers, A.; Keegstra, H.; Renardus, M.K.R. Gromacs—A Parallel Computer for Molecular-Dynamics Simulations; World Scientific Publishing: Singapore, 1993; pp. 252–256. ISBN 981-02-1245-3.

43. Huang, J.; MacKerell, A.D. CHARMM36 all-atom additive protein force field: Validation based on comparison to NMR data. J. Comput. Chem. 2013, 34, 2135–2145. [CrossRef]

44. Pettersen, E.F.; Goddard, T.D.; Huang, C.C.; Couch, G.S.; Greenblatt, D.M.; Meng, E.C.; Ferrin, T.E. UCSF Chimera—a visualization system for exploratory research and analysis. J. Comput. Chem. 2004, 25, 1605–1612. [CrossRef]

45. Elfiky, A.A.; Mahran, H.A.; Ibrahim, I.M.; Ibrahim, M.N.; Elshemy, W.M. Molecular dynamics simulations and MM-GBSA reveal novel guanosine derivatives against SARS-CoV-2 RNA dependent RNA polymerase. RSC Adv. 2022, 12, 2741–2750. [CrossRef] [PubMed]

46. Seeliger, D.; de Groot, B.L. Ligand docking and binding site analysis with PyMOL and Autodock/Vina. J. Comput. Mol. Des. 2010, 24, 417–422. [CrossRef] [PubMed]

47. Adasme, M.F.; Linnemann, K.L.; Bolz, S.N.; Kaiser, F.; Salentin, S.; Haupt, V.J.; Schroeder, M. PLIP 2021: Expanding the scope of the protein-ligand interaction profiler to DNA and RNA. Nucleic Acids Res. 2021, 49, W530–W534. [CrossRef] [PubMed]

48. Salentin, S.; Schreiber, S.; Haupt, V.J.; Adasme, M.F.; Schroeder, M. PLIP: Fully automated protein–ligand interaction profiler. Nucleic Acids Res. 2015, 43, W443–W447. [CrossRef]